TEST:

COLOTECT™ 1.0

This study highlighted the better performance of COLOTECT than FIT in detecting CRC. Additionally, given its lower cost and higher acceptance, the COLOTECT strategy might be more cost-effective than colonoscopy for massive CRC screening.

Overall, participants reflected positive attitudes and perceptions toward Colotect use, along with identifying difficulties associated with its use. Modifications to test kits were proposed corresponding to the issues identified. In summary, this study demonstrated the feasibility and acceptability of using Colotect in CRC screening program. Future studies should examine the applicability, acceptability, efficiency, and cost-effectiveness of the test in real-world settings.

"Novazym Laboratory from Poznań and the Polish Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw have started cooperating on a screening study in which the effectiveness of COLOTECT™ 1.0 test is compared with colonoscopy."

In conclusion, preliminary real-world evidence suggested that fecal DNA tests had promising diagnostic yield in population-based CRC screening. https://www.chictr.org.cn/showproj.html?proj=192838, identifier ChiCTR2300070520.

"Brunei Darussalam's healthcare landscape achieved another significant feat with the launch of the Borneo Genomics Innovation Sdn Bhd (BGIB) Molecular Testing Lab on August 16, 2023, a state-of-the-art laboratory offering invasive prenatal testing, screening for Down syndrome, detection of human papillomavirus (HPV) and COLOTECT, a non-invasive method of screening for colorectal cancer."

Compared to a national CRC program implemented in Hubei Province between 2018 and 2019 using fecal immunochemical tests and CRC risk assessment questionnaires, current program showed a lower initial positive rate (4.4% vs. 17.4%), higher PPVs for CRC (1.3% vs. 0.08%) in the age-matched group, and a higher adherence rate for colonoscopy (71.3% vs. 18.2%). Conclusions Preliminary prospective evidence suggested that fecal DNA tests had promising diagnostic yield in population-based CRC screening, outperforming FIT/risk assessment questionnaire-based screening strategy.

"BGI Genomics is pleased to announce that its proprietary COLOTECT DNA methylation-based test DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C GENES (Real-time PCR) has been listed on the Australian Register of Therapeutic Goods (ARTG) from Australia’s regulatory authority Therapeutic Goods Administration (TGA)."

"Recently, BGI Genomics' COLOTECT™ 1.0 DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes (Real-Time PCR), Sample Pretreatment Kit for Methylation Detection, DNA Isolation Kit, Stool Sample Collection Kit have received market authorization from Malaysia's Medical Device Authority...With this certification, COLOTECT™ 1.0 is now available in over six countries/regions and markets that recognize these certificates."

"BGI Genomics is pleased to announce the launch of COLOTECT 1.0 in Slovakia, in collaboration with its local partner, Zentya...COLOTECT 1.0 is one of the first-ever fecal DNA tests for colorectal cancer that is available in the country. It is a non-invasive fecal DNA test developed by BGI Genomics for detecting colorectal cancer and precancerous lesions. It uses multiplex methylation-specific PCR (MSP) technology to trace abnormal colorectal cancer DNA-methylation biomarkers from fecal samples."